Symbiotec Pharmalab IPO Subscription Status
Final figures at close of bidding: 1 Sept 2026, 6:30 pm IST
| Category | Subscription |
|---|---|
| QIB | 181.2x |
| NII | 77.56x |
| sNII (₹2L–₹10L) | 58.01x |
| bNII (above ₹10L) | 87.34x |
| Retail (RII) | 13.69x |
| Employee | 16.32x |
| Total | 75.08x |
Bidding day 4
Day-wise subscription
| Day | QIB | sNII | bNII | Retail | Employee | Total |
|---|---|---|---|---|---|---|
| Day 1 | 0.37x | 1.66x | 0.82x | 1.01x | 1.65x | 0.85x |
| Day 2 | 0.57x | 4.3x | 2.59x | 2.22x | 3.19x | 1.95x |
| Day 3 | 0.62x | 14.78x | 11.9x | 5.38x | 6.25x | 5.62x |
| Day 4 | 181.2x | 58.01x | 87.34x | 13.69x | 16.32x | 75.08x |
Times subscribed per category (bids vs shares offered, anchor portion excluded). Bidding has closed — these are the final figures.
How the book filled
Day-by-day demand
The Symbiotec Pharmalab book was built over 4 days: overall subscription stood at 0.85× at the close of day 1, read 1.95× at the end of day 2, read 5.62× at the end of day 3, and finished at 75.08× on day 4. On the final day it was qualified institutional buyers (QIB) driving the book, at 181.2× of the shares set aside for the category. More than half of the final demand arrived after day 1 — a late-building book. The largest single-day addition came on day 4, when the overall multiple moved from 5.62× to 75.08×.
Category detail
Qualified institutional buyers took their portion to 181.2×. Non-institutional investors came in at 77.56×, split 58.01× in the small-NII bucket (bids under ₹10 lakh) and 87.34× among big NIIs (above ₹10 lakh). Within the NII book, the bigger ₹10-lakh-plus bids outpaced the smaller applications. Retail investors put in bids for 13.69× the shares reserved for them. Reserved portions ended with the employee quota at 16.32×. That puts qualified institutional buyers (QIB) at the top of the book at 181.2× and retail investors at the bottom at 13.69×.
What the multiple means for allotment
With retail subscription at 13.69×, applications in that category exceeded the shares available to it by a factor of about 13.69. When a retail book is oversubscribed, the registrar does not allot proportionately — allotment runs as a computerised lottery among all valid applications, with each successful application receiving at least one lot of 15 shares — ₹14,820 of stock at the upper band. The multiple above is the data point that determines how thinly that draw is spread; it describes the final book, not the outcome of any single application.
Frequently asked questions
- When does the Symbiotec Pharmalab IPO open and close?
- The Symbiotec Pharmalab IPO opens on 24 Aug 2026 and closes on 27 Aug 2026.
- How many times was the Symbiotec Pharmalab IPO subscribed?
- The Symbiotec Pharmalab IPO was subscribed 75.08 times in total across all investor categories.
- What is the reservation split in the Symbiotec Pharmalab IPO?
- Of the total shares offered, retail investors get 34.93%, QIBs 19.96% (plus 29.94% anchor), non-institutional investors 14.97%.